Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Impact on Dyskinesia
Objective: Assess impact of apomorphine sublingual film (APL) on time spent with and functional impact of dyskinesia among patients with Parkinson’s disease (PD) and “OFF”…Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Effect on MDS-UPDRS Part III Subdomains
Objective: Evaluate effect of apomorphine sublingual film (APL-130277; APL) as an on-demand treatment of “OFF” episodes in patients with Parkinson’s disease (PD) on MDS-UPDRS Part…Dose Optimization of Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients with Parkinson’s Disease: Clinical and Exposure Response Findings
Objective: Evaluate if dose optimization (DO) of apomorphine sublingual film (APL-130277; APL) can achieve improved FULL “ON” response in patients with Parkinson’s disease (PD) and…A Discrete-Choice Experiment Evaluating Preferences for On-Demand Treatments for Patients with Parkinson’s Disease and “OFF” Episodes
Objective: To quantify patient preferences for on-demand treatments among patients with Parkinson’s disease (PD) and “OFF” episodes. Background: Patients with PD develop potentially disabling “OFF”…Budget Impact of Apomorphine Sublingual Film for On-Demand Treatment of Patients With Parkinson’s Disease and “OFF” Episodes
Objective: To estimate the budget impact of introducing apomorphine sublingual film (APL-130277; APL) as an on-demand treatment for patients with Parkinson’s disease (PD) and “OFF”…On-Demand Treatment Preferences of Patients with Parkinson’s Disease and “OFF” Episodes: Heterogeneity Across Patient Subgroups
Objective: To quantify preference heterogeneity for on-demand treatments among patients with Parkinson’s disease (PD) and “OFF” episodes. Background: Patients with PD commonly experience “OFF” episodes.…Randomized, placebo-controlled study investigating the safety, pharmacokinetics and efficacy of inhaled apomorphine in Parkinson’s disease patients
Objective: To evaluate the safety, pharmacokinetics (PK) and efficacy of single-dose apomorphine inhalation in PD patients. Background: Apomorphine is a dopamine agonist, approved for treating…Spontaneous smoking cessation in a parkinsonian patient treated with apomorphine pump
Objective: To describe the case of a parkinsonian patient treated by apomorphine pump who stopped smoking without difficulty despite being dependent to nicotine. To explore…What is holding back apomorphine therapy for Parkinson’s disease? Identifying knowledge gaps amongst Thai neurological medical professionals
Objective: To assess the level of understanding about, and identify knowledge gaps in, apomorphine therapy amongst Thai neurological medical professionals. Background: Continuous subcutaneous apomorphine infusion…The Indian Experience of Continuous Dopaminergic therapy with Apomorphine in Parkinson’s Disease
Objective: A clinical audit of apomorphine pumps – The Indian experience. Background: Continuous dopaminergic therapy remains crucial in the management of moderately advanced Parkinson’s disease…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 13
- Next Page »